Compare Kaltura Inc (KLTR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kaltura Inc trades at $1.38 (market cap $210.52M), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 34.9× Kaltura Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KLTR | SYRE | |
|---|---|---|
Market Cap | $210.52M | $7.35B |
Volume | 330,932 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $1.89 | $108.92 |
52-Week Low | $1.08 | $22.18 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $222.73M | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.37, down 2.14% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company maintains strong revenue around $181M annually with improving net losses, though profitability remains negative. Recent positive developments include AI platform awards and major streaming contracts, while analyst sentiment is cautiously optimistic with 44% buy ratings.
Kaltura presents a turnaround story with improving financials and AI-driven growth initiatives, but faces significant execution risks amid persistent losses. The stock offers speculative upside if AI investments translate to profitability, though high valuation ratios and negative ROE warrant caution for risk-averse investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
